Drug Profile
Research programme: RL21A antibody therapeutic - Catalent/Pure MHC
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Pure MHC
- Developer Catalent Pharma Solutions; Pure MHC
- Class Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 20 Jul 2016 Preclinical trials in Cancer in USA (unspecified route)